WallStreetZenWallStreetZen

NASDAQ: MIST
Milestone Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MIST

Based on 3 analysts offering 12 month price targets for Milestone Pharmaceuticals Inc

Min Forecast
$8.00+339.56%
Avg Forecast
$8.00+339.56%
Max Forecast
$8.00+339.56%

Should I buy or sell MIST stock?

Based on 3 analysts offering ratings for Milestone Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MIST's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MIST as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their MIST stock forecasts and price targets.

MIST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-06
lockedlocked$00.00+00.00%2025-12-16Find Out Why
lockedlocked$00.00+00.00%2025-12-15

1 of 1

Forecast return on equity

Is MIST forecast to generate an efficient return?

Company
224.59%
Industry
310.8%
Market
238.59%
MIST's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MIST forecast to generate an efficient return on assets?

Company
52.47%
Industry
115.15%
MIST is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MIST earnings per share forecast

What is MIST's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.52
Avg 2 year Forecast
-$0.82
Avg 3 year Forecast
-$0.60

MIST revenue forecast

What is MIST's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$27.1M
Avg 2 year Forecast
$30.4M
Avg 3 year Forecast
$107.6M

MIST vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MIST$1.82$8.00+339.56%Strong Buy
ABOS$2.56$7.50+192.97%Strong Buy
TLSA$1.39N/AN/A
IPSC$1.79$3.00+67.60%Buy
RANI$1.29$10.50+713.95%Strong Buy
View Top Biotech Stocks

Milestone Pharmaceuticals Stock Forecast FAQ

Is Milestone Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MIST) stock is to Strong Buy MIST stock.

Out of 3 analysts, 2 (66.67%) are recommending MIST as a Strong Buy, 1 (33.33%) are recommending MIST as a Buy, 0 (0%) are recommending MIST as a Hold, 0 (0%) are recommending MIST as a Sell, and 0 (0%) are recommending MIST as a Strong Sell.

If you're new to stock investing, here's how to buy Milestone Pharmaceuticals stock.

What is MIST's earnings growth forecast for 2026-2028?

(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.

Milestone Pharmaceuticals's earnings in 2026 is -$58,012,000.On average, 7 Wall Street analysts forecast MIST's earnings for 2026 to be -$44,654,287, with the lowest MIST earnings forecast at -$81,796,638, and the highest MIST earnings forecast at -$8,048,503. On average, 6 Wall Street analysts forecast MIST's earnings for 2027 to be -$70,153,989, with the lowest MIST earnings forecast at -$100,993,808, and the highest MIST earnings forecast at -$54,550,965.

In 2028, MIST is forecast to generate -$50,820,548 in earnings, with the lowest earnings forecast at -$101,828,468 and the highest earnings forecast at $4,471,391.

What is MIST's revenue growth forecast for 2026-2028?

(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.42%.

Milestone Pharmaceuticals's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast MIST's revenue for 2026 to be $2,308,685,408, with the lowest MIST revenue forecast at $333,863,828, and the highest MIST revenue forecast at $7,279,423,832. On average, 6 Wall Street analysts forecast MIST's revenue for 2027 to be $2,593,151,017, with the lowest MIST revenue forecast at $1,752,785,100, and the highest MIST revenue forecast at $3,577,112,448.

In 2028, MIST is forecast to generate $9,165,073,108 in revenue, with the lowest revenue forecast at $5,341,821,256 and the highest revenue forecast at $15,355,181,030.

What is MIST's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MIST) forecast ROA is 52.47%, which is lower than the forecast US Biotechnology industry average of 115.15%.

What is MIST's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MIST price target, the average MIST price target is $8.00, with the highest MIST stock price forecast at $8.00 and the lowest MIST stock price forecast at $8.00.

On average, Wall Street analysts predict that Milestone Pharmaceuticals's share price could reach $8.00 by Jan 6, 2027. The average Milestone Pharmaceuticals stock price prediction forecasts a potential upside of 339.56% from the current MIST share price of $1.82.

What is MIST's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MIST) Milestone Pharmaceuticals's current Earnings Per Share (EPS) is -$0.82. On average, analysts forecast that MIST's EPS will be -$0.52 for 2026, with the lowest EPS forecast at -$0.96, and the highest EPS forecast at -$0.09. On average, analysts forecast that MIST's EPS will be -$0.82 for 2027, with the lowest EPS forecast at -$1.19, and the highest EPS forecast at -$0.64. In 2028, MIST's EPS is forecast to hit -$0.60 (min: -$1.20, max: $0.05).

What is MIST's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MIST) forecast ROE is 224.59%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.